Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs Victoria's Secret & Co (VSXY) Price & Performance

ResMed Inc.Trade
Victoria's Secret & CoTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs Victoria's Secret & Co — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Victoria's Secret & Co trades at $82.86 (market cap $6.91B). The key difference: ResMed Inc. is far larger — about 4.6× Victoria's Secret & Co's market cap, and ResMed Inc. pays a 1.16% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Victoria's Secret & Co for 34 Days on average.

RMDVSXY
Market Cap
$31.89B$6.91B
Volume
618,3141,346,928
Sector
HealthConsumer Cyclical
52-Week High
$277.88$99.97
52-Week Low
$182.82$28.25
Typical Hold Time
51 Days34 Days
Enterprise Value
$31.24B$9.29B
Dividend Yield
1.16%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.

The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.

Victoria's Secret & Co

Victoria's Secret (VSXY) trades at $82.87, down 3.4% on the day, but maintains strong analyst support with a 60% buy rating and $86.80 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q4 2025 and Q1-Q2 2026, while fundamentals reveal improving profitability with 39.57% gross margins and 45.27% ROE. Recent news highlights brand momentum through fashion show expansions and omnichannel retail growth.

The outlook remains positive with projected 2026 revenue growth to $6.9B and net income of $378M, though risks include elevated valuation metrics (P/E 19.33) and competitive pressures. Institutional interest is strengthening with recent investments from Tidal Investments and California State Teachers Retirement System, supporting the bullish case for long-term investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RMD

No sentiment data available yet.

VSXY
96% Buy4% Sell
Avg holding period · 34 Days

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD →

About Victoria's Secret & Co

Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.

Read more on VSXY →